Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Down 30.2% in October

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 276,200 shares, a decline of 30.2% from the September 30th total of 395,900 shares. Approximately 5.0% of the shares of the company are short sold. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 5.0% of the shares of the company are short sold.

Liminatus Pharma Stock Down 5.0%

Shares of Liminatus Pharma stock traded down $0.07 on Monday, hitting $1.32. The company’s stock had a trading volume of 280,603 shares, compared to its average volume of 501,413. Liminatus Pharma has a 1 year low of $1.11 and a 1 year high of $33.66. The firm’s fifty day moving average is $1.78. The firm has a market cap of $35.73 million and a P/E ratio of -26.40.

Liminatus Pharma (NASDAQ:LIMN) last announced its quarterly earnings results on Friday, October 3rd. The company reported ($0.05) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

LIMN has been the subject of several analyst reports. Wall Street Zen raised Liminatus Pharma from a “sell” rating to a “hold” rating in a report on Saturday, August 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liminatus Pharma in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Liminatus Pharma has an average rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.